Omics-Based Clinical Trials Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Size, Share & Trends, Drivers, Restraints, Opportunities, Manufacturer, Applications, And Segments

  • AMR-1067532
  • January 2022
  • Pharmaceuticals
  • 124 Pages
Report Description

This report is a comprehensive study that examines the Omics-Based Clinical Trials industry in depth. With reference to key regions and major nations, the study specifies the product type of Omics-Based Clinical Trials as well as its use in various industrial verticals. Furthermore, the report identified and analysed all of the top companies functioning in the global Omics-Based Clinical Trials market arena, comparing and contrasting them based on market revenue, yearly sales volume, historical growth rate, and company strategies. The worldwide Omics-Based Clinical Trials market research offers a business strategy for current market participants to strengthen their market positions based on all of these findings. Furthermore, the paper recommends a market entry strategy for newcomers to the sector.

The top vendors and distributors operating in all of the major regions have also been highlighted in the Omics-Based Clinical Trials market report. This data and research should aid market players in strengthening their market distribution networks and expanding their geographic reach.
 
Omics-Based Clinical Trials Market Strategic Analysis 

The market was studied using several marketing methodologies such as Porter's Five Forces Analysis, player positioning analysis, SWOT analysis, market share analysis, and value chain analysis in the Omics-Based Clinical Trials market study. The market dynamics and factors such as the threat of a Omics-Based Clinical Trials substitute, the threat of new entrants into the Omics-Based Clinical Trials market, buyer bargaining power, supplier bargaining power to Omics-Based Clinical Trials providing companies, and internal rivalry among Omics-Based Clinical Trials providers are analysed in Porter's Five Forces analysis to provide the report's readers with a detailed view of the current market dynamics.

This analysis assists report users in evaluating the Omics-Based Clinical Trials market based on various parameters such as economies of scale, switching costs, brand loyalty, existing distribution channels, capital investments, manufacturing rights & patents, government regulations, advertising impact, and consumer preference impact. This simplified data is expected to aid the industry's key decision-makers in their decision-making process. Furthermore, this study answers the crucial question of whether or not new entrants should enter the Omics-Based Clinical Trials industry.
 
Omics-Based Clinical Trials Market Key Trends Analysis

The important factors influencing the growth of the Omics-Based Clinical Trials market have been examined in this report. The driving factors that are boosting demand for Omics-Based Clinical Trialss and the restraining factors that are slowing growth of the Omics-Based Clinical Trials industry are addressed in depth, as well as their implications for the worldwide Omics-Based Clinical Trials market. In addition, the published analysis identifies and discusses in detail the trends that are driving the market and impacting its growth. In addition, other qualitative variables such as risks connected with operations and key problems faced by market players are covered in the report.

Omics-Based Clinical Trials Market Key Segment Analysis

By segmenting the market by product type, application, and geography, the study provides a clear picture of the Omics-Based Clinical Trials industry. On the basis of current and future trends, all segments of the Omics-Based Clinical Trials industry have been examined. The market and its divisions are forecasted for the years 2021 through 2028. The study identifies the categories that are contributing the most to total market revenue growth, as well as the factors that are supporting their growth.

The research will provide a detailed qualitative and quantitative product type segment analysis for the years 2021 to 2028.

The report study analyses and includes a variety of prospective prospects and aspects affecting various applications.
 
Omics-Based Clinical Trials Market Regional Trends and Market Player’s Analysis

North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa are the regions in which the market is divided. In 2020, the worldwide Omics-Based Clinical Trials market was dominated by North America. The Asia Pacific region is expected to have the highest CAGR for the Omics-Based Clinical Trials market throughout the projected period.


 
The market revenue, market shares, business strategies, recent developments, and growth rates of major players with substantial market shares in the global Omics-Based Clinical Trials market are all examined. These firms' recent developments, such as new solution/product launches, research projects, acquisitions, geographic expansions, and technological advancements, are taken into account when determining their position in the Omics-Based Clinical Trials market. All important stakeholders in the Omics-Based Clinical Trials value chain and technological ecosystem are expected to benefit from the insights offered in the Omics-Based Clinical Trials market research study.

In order to provide a broader understanding of the top competitors in the Omics-Based Clinical Trials market, the research includes a company market share analysis. Parexel International Corporation, Pharmaceutical Product Development (PPD), Charles River Laboratory, ICON plc, SGS SA, Eli Lilly and Company, Pfizer Inc., Merck & Co., Inc., Covance Inc., Novo Nordisk, Rebus Bio are among the major participants in the global Omics-Based Clinical Trials industry.
 
Scope of the report
Report Parameters Details of Parameter
Market Size xx Million
Based Year 2021
Forecast Period Covered 2021-2028
Units for value Revenue in USD million and CAGR from 2021 to 2028
Covered Segments Component, Types, Applications, End-Users, and more.
Region Covered North America, Europe, Asia Pacific, Latin America, Middle East and Africa
Companies Covered Parexel International Corporation, Pharmaceutical Product Development (PPD), Charles River Laboratory, ICON plc, SGS SA, Eli Lilly and Company, Pfizer Inc., Merck & Co., Inc., Covance Inc., Novo Nordisk, Rebus Bio
 
Major Highlights of the Omics-Based Clinical Trials Market report study:
  • An in-depth examination of the global Omics-Based Clinical Trials industry will be published soon.
  • The study examines the global Omics-Based Clinical Trials market and offers major actionable information to its players.
  • The research has taken into account all key events in the recent past, providing users with up-to-date industry information.
  • The report study is expected to aid the industry's key decision-makers in their decision-making process.
  • Data on market intelligence, changing market dynamics, existing and predicted market trends, and so on are included in the report.
  • The research includes a detailed examination of the macroeconomic and microeconomic aspects that influence the global Omics-Based Clinical Trials industry.
  • The Market Ecosystem and Adoption in Different Markets
  • The global Omics-Based Clinical Trials market is being shaped by several major trends.
  • The size of the Omics-Based Clinical Trials market in terms of revenue has been measured in the past and will be measured in the future in USD million.
  • Consumer preference patterns and recent industrial developments
  • The worldwide Omics-Based Clinical Trials market's competitive landscape and player positioning analysis
  • Major players' key goods and solutions, as well as their business strategies
  • Recommendations for new market entrants as well as existing market participants.
  • The study of niche and potential segments (product type, application, and regions/countries) predicts that promising growth will be noticed.
  • Operating players in the market encounter a number of significant hurdles.
  • An examination of the major risks involved in market operations
 
The report segment of the global Omics-Based Clinical Trials market as follows:
Global Omics-Based Clinical Trials Market: By Product Type

  • Type I
  • Type II
  • Type III

Global Omics-Based Clinical Trials Market: By Application
  • Application I
  • Application II
  • Application III

Global Omics-Based Clinical Trials Market: By Region
  • North America
    • U.S.
    • Canada
    • Rest of North America
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China 
    • Japan
    • India
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Argentina
    • Rest of Latin America
  • Middle East and Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

The report study is drafted to provide actionable insights to the following mentioned audience:
  • Institutes of research and consulting firms
  • Companies are attempting to get into the Omics-Based Clinical Trials market.
  • Universities and students
  • Other companies in the Omics-Based Clinical Trials market include solution providers, product producers, service providers, and others.
  • Private companies and government agencies that are linked
  • Individuals interested in learning more about the Omics-Based Clinical Trials market

Manufacturers and Segments

  • Parexel International Corporation
  • Pharmaceutical Product Development (PPD)
  • Charles River Laboratory
  • ICON plc
  • SGS SA
  • Eli Lilly and Company
  • Pfizer Inc.
  • Merck & Co., Inc.
  • Covance Inc.
  • Novo Nordisk
  • Rebus Bio
  • Type I
  • Type II
  • Type III
  • Application I
  • Application II
  • Application III

Have query on this report?

Make an Enquiry
1. Preface
     1.1. Report Scope and Description
     1.2. Research Methodology
          1.2.1. Phase I-Secondary Research
          1.2.2. Phase II-Primary Research
          1.2.3. Phase II-Expert Panel Review
          1.2.4. Assumptions
          1.2.5. Approach Adopted

2. Executive Summarysegment Form
     2.1. Global Omics-Based Clinical Trials Market Snapshot
          2.1.1. Global Omics-Based Clinical Trials Market By Type I,2019
               2.1.1.1.
               2.1.1.2.Type I I
               2.1.1.3.Type I II
          2.1.2. Global Omics-Based Clinical Trials Market By Application I,2019
               2.1.2.1.
               2.1.2.2.Application I I
               2.1.2.3.Application I II
          2.1.3. Global Omics-Based Clinical Trials Market By End-use,2019
          2.1.4. Global Omics-Based Clinical Trials Market By Geography,2019

3. Global Omics-Based Clinical Trials Market Dynamics
     3.1. Market Overview
     3.2. Market Inclination Insights Analysis
     3.3. Drivers
     3.4. Challenges
     3.5. Future Prospects
     3.6. Impact Analysis of Drivers and Challenges During the Forecast Period, (2020-2028)

4. Global Omics-Based Clinical Trials Market Size (US$), By Type I, 2018 – 2028 
     4.1. Overview
          4.1.1. Market Share Analysis By Type I, 2019 vs.2028
          4.1.2. Attractive Investment Proposition By Type I, 2020
     4.2. Global Omics-Based Clinical Trials Market Size (US$), By Type I, 2018 – 2028

5. Global Omics-Based Clinical Trials Market Size (US$), By Application I, 2018 – 2028 
     5.1. Overview
          5.1.1. Market Share Analysis By Application I, 2019 vs.2028
          5.1.2. Attractive Investment Proposition By Application I, 2020
     5.2. Global Omics-Based Clinical Trials Market Size (US$), By Application I, 2018 – 2028

6. Global Omics-Based Clinical Trials Market Size (US$), By End-use, 2018 – 2028 
     6.1. Overview
          6.1.1. Market Share Analysis By End-use, 2019 vs.2028
          6.1.2. Attractive Investment Proposition By End-use, 2020
     6.2. Global Omics-Based Clinical Trials Market Size (US$), By End-use, 2018 – 2028

7. Global Omics-Based Clinical Trials Market Size (US$), By Geography, 2018 – 2028
     7.1. Overview
          7.1.1. Market Share Analysis by Geography, 2019 vs. 2028
          7.1.2. Attractive Investment Proposition by Geography, 2020
     7.2. North America Omics-Based Clinical Trials Market Analysis, 2018 – 2028 
          7.2.1. North America Omics-Based Clinical Trials Market Size (US$), By Country, 2018 – 2028 
               7.2.1.1. U.S.
               7.2.1.2. Canada
          7.2.2. North America Omics-Based Clinical Trials Market Size (US$), By Type I, 2018 – 2028
          7.2.3. North America Omics-Based Clinical Trials Market Size (US$), By Application I, 2018 – 2028
          7.2.4. North America Omics-Based Clinical Trials Market Size (US$), By End-use, 2018 – 2028
     7.3. Europe Omics-Based Clinical Trials Market Analysis, 2018 – 2028 
          7.3.1.  Europe Omics-Based Clinical Trials Market Size (US$), By Country, 2018 – 2028 
               7.3.1.1. U.K.
               7.3.1.2. Germany
               7.3.1.3. France
               7.3.1.4. Rest of Europe
          7.3.2. Europe Omics-Based Clinical Trials Market Size (US$), By Type I, 2018 – 2028
          7.3.3. Europe Omics-Based Clinical Trials Market Size (US$), By Application I, 2018 – 2028
          7.3.4. Europe Omics-Based Clinical Trials Market Size (US$), By End-use, 2018 – 2028
     7.4. Asia Pacific Omics-Based Clinical Trials Market Analysis , 2018 – 2028
          7.4.1.  Asia Pacific Omics-Based Clinical Trials Market Size (US$), By Country, 2018 – 2028 
               7.4.1.1. China
               7.4.1.2. Japan
               7.4.1.3. India
               7.4.1.4. Rest of Asia Pacific
          7.4.2. Asia Pacific Omics-Based Clinical Trials Market Size (US$), By Type I, 2018 – 2028
          7.4.3. Asia Pacific Omics-Based Clinical Trials Market Size (US$), By Application I, 2018 – 2028
          7.4.4. Asia Pacific Omics-Based Clinical Trials Market Size (US$), By End-use, 2018 – 2028
     7.5. Latin America Omics-Based Clinical Trials Market Analysis, 2018 – 2028 
          7.5.1.  Latin America Omics-Based Clinical Trials Market Size (US$), By Country, 2018 – 2028 
               7.5.1.1. Brazil
               7.5.1.2. Mexico
               7.5.1.3. Rest of Latin America
          7.5.2. Latin America Omics-Based Clinical Trials Market Size (US$), By Type I, 2018 – 2028
          7.5.3. Latin America Omics-Based Clinical Trials Market Size (US$), By Application I, 2018 – 2028
          7.5.4. Latin America Omics-Based Clinical Trials Market Size (US$), By End-use, 2018 – 2028
     7.6. Middle East & Africa (MEA) Omics-Based Clinical Trials Market Analysis, 2018 – 2028 
          7.6.1.  MEA Omics-Based Clinical Trials Market Size (US$), By Region, 2018 – 2028 
               7.6.1.1. GCC Countries
               7.6.1.2. South Africa
               7.6.1.3. Rest of MEA
          7.6.2. MEA Omics-Based Clinical Trials Market Size (US$), By Type I, 2018 – 2028
          7.6.3. MEA Omics-Based Clinical Trials Market Size (US$), By Application I, 2018 – 2028
          7.6.4. MEA Omics-Based Clinical Trials Market Size (US$), By End-use, 2018 – 2028

8. Company Profiles
     8.1. Competitive Analysis 
     8.2. Market Positioning of Key Vendors 
     8.3. Key Strategies adopted by the Leading Players
     8.4. Key Omics-Based Clinical Trials Providers
        8.4.1 Parexel International Corporation
                8.4.1.1 Business Description
                8.4.1.2 Parexel International Corporation Geographic Operations
                8.4.1.3 Parexel International Corporation Financial Information
                8.4.1.4 Parexel International Corporation Product Positions/Portfolio
                8.4.1.5 Parexel International Corporation Key Developments
        8.4.2 Pharmaceutical Product Development (PPD)
                8.4.2.1 Business Description
                8.4.2.2 Pharmaceutical Product Development (PPD) Geographic Operations
                8.4.2.3 Pharmaceutical Product Development (PPD) Financial Information
                8.4.2.4 Pharmaceutical Product Development (PPD) Product Positions/Portfolio
                8.4.2.5 Pharmaceutical Product Development (PPD) Key Developments
        8.4.3 Charles River Laboratory
                8.4.3.1 Business Description
                8.4.3.2 Charles River Laboratory Geographic Operations
                8.4.3.3 Charles River Laboratory Financial Information
                8.4.3.4 Charles River Laboratory Product Positions/Portfolio
                8.4.3.5 Charles River Laboratory Key Developments
        8.4.4 ICON plc
                8.4.4.1 Business Description
                8.4.4.2 ICON plc Geographic Operations
                8.4.4.3 ICON plc Financial Information
                8.4.4.4 ICON plc Product Positions/Portfolio
                8.4.4.5 ICON plc Key Developments
        8.4.5 SGS SA
                8.4.5.1 Business Description
                8.4.5.2 SGS SA Geographic Operations
                8.4.5.3 SGS SA Financial Information
                8.4.5.4 SGS SA Product Positions/Portfolio
                8.4.5.5 SGS SA Key Developments
        8.4.6 Eli Lilly and Company
                8.4.6.1 Business Description
                8.4.6.2 Eli Lilly and Company Geographic Operations
                8.4.6.3 Eli Lilly and Company Financial Information
                8.4.6.4 Eli Lilly and Company Product Positions/Portfolio
                8.4.6.5 Eli Lilly and Company Key Developments
        8.4.7 Pfizer Inc.
                8.4.7.1 Business Description
                8.4.7.2 Pfizer Inc. Geographic Operations
                8.4.7.3 Pfizer Inc. Financial Information
                8.4.7.4 Pfizer Inc. Product Positions/Portfolio
                8.4.7.5 Pfizer Inc. Key Developments
        8.4.8 Merck & Co., Inc.
                8.4.8.1 Business Description
                8.4.8.2 Merck & Co., Inc. Geographic Operations
                8.4.8.3 Merck & Co., Inc. Financial Information
                8.4.8.4 Merck & Co., Inc. Product Positions/Portfolio
                8.4.8.5 Merck & Co., Inc. Key Developments
        8.4.9 Covance Inc.
                8.4.9.1 Business Description
                8.4.9.2 Covance Inc. Geographic Operations
                8.4.9.3 Covance Inc. Financial Information
                8.4.9.4 Covance Inc. Product Positions/Portfolio
                8.4.9.5 Covance Inc. Key Developments
        8.4.10 Novo Nordisk
                8.4.10.1 Business Description
                8.4.10.2 Novo Nordisk Geographic Operations
                8.4.10.3 Novo Nordisk Financial Information
                8.4.10.4 Novo Nordisk Product Positions/Portfolio
                8.4.10.5 Novo Nordisk Key Developments
        8.4.11 Rebus Bio
                8.4.11.1 Business Description
                8.4.11.2 Rebus Bio Geographic Operations
                8.4.11.3 Rebus Bio Financial Information
                8.4.11.4 Rebus Bio Product Positions/Portfolio
                8.4.11.5 Rebus Bio Key Developments

LIST OF TABLES

TABLE 1 Market Snapshot: Global Omics-Based Clinical Trials Market 
TABLE 2 Impact Indicators 
TABLE 3 Impact Analysis of Drivers and Restraints 
TABLE 4 North America Omics-Based Clinical Trials Market Revenue, By Type I, 2018 – 2028 (US$ Mn) 
TABLE 5 North America Omics-Based Clinical Trials Market Revenue, By Application I, 2018 – 2028 (US$ Mn) 
TABLE 6 North America Omics-Based Clinical Trials Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 7 Europe Omics-Based Clinical Trials Market Revenue, By Type I, 2018 – 2028 (US$ Mn) 
TABLE 8 Europe Omics-Based Clinical Trials Market Revenue, By Application I, 2018 – 2028 (US$ Mn) 
TABLE 9 Europe Omics-Based Clinical Trials Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 10 Asia Pacific Omics-Based Clinical Trials Market Revenue, By Type I, 2018 – 2028 (US$ Mn) 
TABLE 11 Asia Pacific Omics-Based Clinical Trials Market Revenue, By Application I, 2018 – 2028 (US$ Mn) 
TABLE 12 Asia Pacific Omics-Based Clinical Trials Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 13 Latin America Omics-Based Clinical Trials Market Revenue, By Type I, 2018 – 2028 (US$ Mn) 
TABLE 14 Latin America Omics-Based Clinical Trials Market Revenue, By Application I, 2018 – 2028 (US$ Mn) 
TABLE 15 Latin America Omics-Based Clinical Trials Market Revenue, By End-use, 2018 – 2028 (US$ Mn)
TABLE 16 MEA Omics-Based Clinical Trials Market Revenue, By Type I, 2018 – 2028 (US$ Mn) 
TABLE 17 MEA Omics-Based Clinical Trials Market Revenue, By Application I, 2018 – 2028 (US$ Mn) 
TABLE 18 MEA Omics-Based Clinical Trials Market Revenue, By End-use, 2018 – 2028 (US$ Mn)

LIST OF FIGURES

FIG. 1 Global Omics-Based Clinical Trials: Market Segmentation 
FIG. 2 Global Omics-Based Clinical Trials Market: Research Methodology 
FIG. 3 Top-Down and Bottom-up Approach 
FIG. 4 Global Omics-Based Clinical Trials Market, By Type I, 2019 (US$ Mn) 
FIG. 5 Global Omics-Based Clinical Trials Market, By Application I, 2019 (US$ Mn) 
FIG. 6 Global Omics-Based Clinical Trials Market, By End-use, 2019 (US$ Mn) 
FIG. 7 Global Omics-Based Clinical Trials Market, By Geography, 2019 (US$ Mn) 
FIG. 8 Global Omics-Based Clinical Trials Market Revenue and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG. 9 Attractive Investment Proposition 
FIG. 10 Market Positioning of Key Omics-Based Clinical Trials Providers, 2019
FIG. 11 Global Omics-Based Clinical Trials Market Revenue Contribution, By Type I, 2019 & 2028 (Value %) 
FIG. 12 Global Omics-Based Clinical Trials Market Revenue Contribution, By Application I, 2019 & 2028 (Value %) 
FIG. 13 Global Omics-Based Clinical Trials Market Revenue Contribution, By End-use, 2019 & 2028 (Value %) 
FIG. 14 North America Omics-Based Clinical Trials Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 15 Europe Omics-Based Clinical Trials Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 16 Asia Pacific Omics-Based Clinical Trials Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 17 Latin America Omics-Based Clinical Trials Market Revenue, 2018 – 2028, (US$ Mn)
FIG. 18 MEA Omics-Based Clinical Trials Market Revenue, 2018 – 2028, (US$ Mn)

Key Takeaways:

1. Market value and estimate of the Omics-Based Clinical Trials market for the period from 2020 to 2028
2. Compounded annual growth rate (CAGR%) for individual segments in various regional markets for a period from 2020 to 2028
3. Value chain analysis
4. Market share study combined with competitive landscape of major players
5. Profiles of major market players covering overall business operations, geographic occurrence, product portfolio, financial status and news coverage 

List of Tables

TABLE  Market Snapshot: Global Omics-Based Clinical Trials Market
TABLE  Impact Pointers
TABLE  Impact Analysis of Drivers and Restraints
TABLE  North America Omics-Based Clinical Trials Market Value, By Segment1, 2018 – 2028
TABLE  North America Omics-Based Clinical Trials Market Value, By Segment2, 2018 – 2028
TABLE  North America Omics-Based Clinical Trials Market Value, By Country, 2018 – 2028
TABLE  Europe Omics-Based Clinical Trials Market Value, By Segment1, 2018 – 2028
TABLE  Europe Omics-Based Clinical Trials Market Value, By Segment2, 2018 – 2028
TABLE  Europe Omics-Based Clinical Trials Market Value, By Country, 2018 – 2028
TABLE  Asia Pacific Omics-Based Clinical Trials Market Value, By Segment1, 2018 – 2028
TABLE  Asia Pacific Omics-Based Clinical Trials Market Value, By Segment2, 2018 – 2028
TABLE  Asia Pacific Omics-Based Clinical Trials Market Value, By Country, 2018 – 2028
TABLE  Latin America Omics-Based Clinical Trials Market Value, By Segment1, 2018 – 2028
TABLE  Latin America Omics-Based Clinical Trials Market Value, By Segment2, 2018 – 2028
TABLE  Latin America Omics-Based Clinical Trials Market Value, By Country, 2018 – 2028
TABLE  MEA Omics-Based Clinical Trials Market Value, By Segment1, 2018 – 2028
TABLE  MEA Omics-Based Clinical Trials Market Value, By Segment2, 2018 – 2028
TABLE  MEA Omics-Based Clinical Trials Market Value, By Country, 2018 – 2028
TABLE  Parexel International Corporation: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Pharmaceutical Product Development (PPD): Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Charles River Laboratory: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  ICON plc: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  SGS SA: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Eli Lilly and Company: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Pfizer Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Merck & Co., Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Covance Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Novo Nordisk: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Rebus Bio: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
 

List of Figures

FIG.  Global Omics-Based Clinical Trials Market: Research Methodology
FIG.  Top-Down and Bottom Up Approach
FIG.  Global Omics-Based Clinical Trials Market, By Segment1, 2019 (US$ Mn)
FIG.  Global Omics-Based Clinical Trials Market, By Segment2, 2019 (US$ Mn)
FIG.  Global Omics-Based Clinical Trials Market, By Geography, 2019 (US$ Mn)
FIG.  Global Omics-Based Clinical Trials Market Value and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG.  Attractive Investment Proposition
FIG.  Market Positioning of Key Omics-Based Clinical Trials Providers, 2016
FIG.  Global Omics-Based Clinical Trials Market Value Share, By Segment1, 2019 & 2028 (% Value)
FIG.  Global Type I Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Type II Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Type III Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Omics-Based Clinical Trials Market Value Share, By Segment2, 2019 & 2028 (% Value)
FIG.  Global Application I Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Application II Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Application III Market Value, 2018 – 2028, (US$ Mn)
FIG.  U.S. Omics-Based Clinical Trials Market Value, 2018 – 2028, (US$ Mn)
FIG.  Canada Omics-Based Clinical Trials Market Value, 2018 – 2028, (US$ Mn)
FIG.  UK Omics-Based Clinical Trials Market Value, 2018 – 2028, (US$ Mn)
FIG.  Germany Omics-Based Clinical Trials Market Value, 2018 – 2028, (US$ Mn)
FIG.  France Omics-Based Clinical Trials Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Europe Omics-Based Clinical Trials Market Value, 2018 – 2028, (US$ Mn)
FIG.  China Omics-Based Clinical Trials Market Value, 2018 – 2028, (US$ Mn)
FIG.  Japan Omics-Based Clinical Trials Market Value, 2018 – 2028, (US$ Mn)
FIG.  India Omics-Based Clinical Trials Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Asia Pacific Omics-Based Clinical Trials Market Value, 2018 – 2028, (US$ Mn)
FIG.  Mexico Omics-Based Clinical Trials Market Value, 2018 – 2028, (US$ Mn)
FIG.  Brazil Omics-Based Clinical Trials Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Latin America Omics-Based Clinical Trials Market Value, 2018 – 2028, (US$ Mn)
FIG.  GCC Countries Omics-Based Clinical Trials Market Value, 2018 – 2028, (US$ Mn)
FIG.  South Africa Omics-Based Clinical Trials Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of MEA Omics-Based Clinical Trials Market Value, 2018 – 2028, (US$ Mn)